ARROW® UltraQuik™ Peripheral Nerve Block Needles Receive FDA 510(k) Clearance Business Wire LIMERICK, Pa. -- January 22, 2013 Teleflex Incorporated (NYSE: TFX) today announced that the ARROW UltraQuik peripheral nerve block (PNB) needles have received 510(k) clearance from the U.S. Food and Drug Administration (FDA). ARROW UltraQuik peripheral nerve block needles are designed to help increase overall block success for clinicians who use ultrasound-guidance when performing single-injection PNBs. UltraQuik needles maintain many of the same clinician-inspired features of the ARROW^® StimuQuik^® ECHO needles, including five grooved rings at the distal tip of the needle to help clinicians identify the needle tip under ultrasound. "Teleflex is pleased to add the ARROW UltraQuik to our line of peripheral nerve block needles," said Cary Vance, President, Anesthesia and Respiratory Division. "The ARROW UltraQuik, StimuQuik and StimuQuik ECHO needles allow us to now offer products to clinicians performing peripheral nerve blocks, whether they use ultrasound only, nerve stimulation only, or a combined approach.” For more information on Teleflex® anesthesia products and educational programs, visit www.teleflex.com. About Teleflex Incorporated Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,100 people worldwide and serves healthcare providers in more than 130 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Arrow, StimuQuik, Teleflex, and UltraQuik are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. ©2013 Teleflex Incorporated. All rights reserved. 2013-1635. Contact: Teleflex Incorporated Jake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836
ARROW® UltraQuik™ Peripheral Nerve Block Needles Receive FDA 510(k) Clearance
Press spacebar to pause and continue. Press esc to stop.